New Therapeutics to Treat Castrate-Resistant Prostate Cancer by Ömer Acar, Tarık Esen, Nathan A. Lack

“…In this review, we will examine mechanistic and clinical data of several newly approved therapeutics including the chemotherapeutic cabazitaxel, antiandrogen enzalutamide, endocrine disruptor abiraterone acetate, immunotherapy sipuleucel-T, and bone-targeting radiopharmaceutical alpharadin. In addition, we will examine other promising therapeutics that are currently in Phase III trials.…”
Get full text

Bone-Targeted Therapies in Metastatic Castration-Resistant Prostate Cancer: Evolving Paradigms by Joelle El-Amm, Ashley Freeman, Nihar Patel, Jeanny B. Aragon-Ching

“…While several radiopharmaceuticals were approved for pain palliation in mCRPC including strontium and samarium, alpharadin is the first radiopharmaceutical to show significant overall survival benefit. …”
Get full text